Mutation Burden and PD-L1 Levels Can Help Predict Patient’s Response to Opdivo, Study Finds
News
Genetic characterization and the detection of PD-1 ligand protein (PD-L1) levels in non-small cell lung cancers (NSCLC) can help oncologists identify those who may benefit the most from Opdivo (nivolumab) ... Read more